IRIDEX provides laser systems, devices and consumables in ophthalmology. Today it has announced its CE Mark to commercialize its Cyclo G6 laser system to treat glaucoma across Europe.
The Cyclo G6 probe uses the company’s MicroPulse technology, which prevents any tissue damage and connects to an external console.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The Cyclo G6 Laser System will be sold with two disposable probes, the MicroPulse P3 probe for use with a broad range of glaucoma patients and the G-Probe for later stage patients. IRIDEX plans to introduce a series of additional new probes in the coming year that allow for additional applications in glaucoma treatment.
As Will Moore, President and Chief Executive Officer of IRIDEX, said in a statement, the Cyclo G6 is a good option for treatment with patients who have not seen significant results from eye drops and do not want surgery. Surgery is clearly invasive, and IRIDEX believes this is an effective solution that negates the need for procedures like implants.
